At least 19 biotechs and pharmas are slated to report earnings this week. Potential takeout target Onyx Pharmaceuticals Inc. (NASDAQ:ONXX) is anticipated to post a smaller loss per share on a 109% increase in revenues to $151.7 million. The biotech, which last year launched Kyprolis carfilzomib for multiple myeloma (MM), in late June rejected an unsolicited bid from Amgen Inc. (NASDAQ:AMGN) (see BioCentury, July 15). The Street expects the company to become profitable in 2014.

Dendreon Corp. (NASDAQ:DNDN), which sells prostate cancer product Provenge sipuleucel-T, is also expected to